Resistentia Pharmaceuticals

About:

Resistentia Pharmaceuticals develops immunotherapeutic products for allergic asthma and inflammatory disorders.

Top Investors: HealthCap, GSK, Industrifonden, Innovations Kapital, BankInvest Biomedical Venture

Description:

Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.